Strategic Partnerships Position Cellaïon as a target for pharma and investment-backed biotech alliances leveraging their phase IIB liver regeneration program and existing funding from Truffle Capital to secure co-development or research collaboration opportunities with larger biopharma and CROs.

Financing Leverage Highlight their substantial funding (~€23M raised in 2022 and additional €5.5M in 2023) to reassure investors and potential partners of financial backing, enabling discussions around milestone-based collaborations, grant support, or joint ventures.

Liver Regeneration Focus Target hepatology and organ repair stakeholders by aligning sales outreach with Hepastem’s immunomodulatory and regenerative properties, emphasizing potential applications in acute on chronic liver failure and liver function restoration programs.

Early Stage Scale Assess opportunities in contract research, platform licensing, and early-access collaborations given the small team size; propose CRO partnerships, pilot studies, or technology licensing to accelerate development while managing burn rate.

Global Market Signals Capitalize on market trends toward advanced therapies and biotech investment by presenting Cellaïon as a high-pidelity partner for translational research, regulatory strategy support, and access to international investors and networks connected to Truffle Capital.